Evotec, Alpine Expand Pact For Commercial Process Development Of Autoimmune Disease Candidate

  • Evotec SE's EVO subsidiary, Just - Evotec Biologics Inc, has expanded a multi-year partnership with Alpine Immune Sciences Inc ALPN for ALPN-303 for systemic lupus erythematosus and other B cell-mediated inflammatory and autoimmune diseases. 
  • The contract is a continuation of their first-in-human program initiated in 2020, in which Just - Evotec Biologics delivered drug substance materials using their J.DESIGN continuous manufacturing platform for Alpine's ongoing Phase 1 study and anticipated Phase 2 studies of ALPN-303.
  • Related: Alpine Immune Sciences' Autoimmune Disease Candidate ALPN-303 Shows Promise in Preclinical Studies.
  • Under the expanded contract, Just - Evotec Biologics will leverage its data-driven technology platform to develop a commercial manufacturing process for ALPN-303. 
  • Commercial process development activities will be performed at Just - Evotec Biologics' J.POD biomanufacturing facility in Redmond, Washington.
  • Price Action: EVO shares are down 12.7% at $12.33 during the premarket session on the last check Wednesday. ALPN stock closed at $8.49 on Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareContractsPre-Market OutlookMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!